ID: ALA5197351

Max Phase: Preclinical

Molecular Formula: C25H31ClN2O4S

Molecular Weight: 491.05

Representations

Canonical SMILES:  CCC(CC)O[C@@H]1C=C(C(=O)O)C[C@H](NCc2ccc(-c3ccsc3)cc2Cl)[C@H]1NC(C)=O

Standard InChI:  InChI=1S/C25H31ClN2O4S/c1-4-20(5-2)32-23-12-19(25(30)31)11-22(24(23)28-15(3)29)27-13-17-7-6-16(10-21(17)26)18-8-9-33-14-18/h6-10,12,14,20,22-24,27H,4-5,11,13H2,1-3H3,(H,28,29)(H,30,31)/t22-,23+,24+/m0/s1

Standard InChI Key:  ZBODECNZYYNPIT-RBZQAINGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 491.05

Molecular Weight (Monoisotopic): 490.1693

AlogP: 5.02

#Rotatable Bonds: 10

Polar Surface Area: 87.66

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.14

CX Basic pKa: 8.11

CX LogP: 2.15

CX LogD: 2.09

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.43

Np Likeness Score: -0.31

References

1. Ju H, Hou L, Zhao F, Zhang Y, Jia R, Guizzo L, Bonomini A, Zhang J, Gao Z, Liang R, Bertagnin C, Kong X, Ma X, Kang D, Loregian A, Huang B, Liu X, Zhan P..  (2022)  Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity.,  65  (17.0): [PMID:35939763] [10.1021/acs.jmedchem.1c01970]

Source

Source(1):

• Scientific Literature